Raltegravir; Abacavir/Lamivudine — Competitive Intelligence Brief

Raltegravir; Abacavir/Lamivudine (Raltegravir; Abacavir/Lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase; HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Raltegravir; Abacavir/Lamivudine (Raltegravir; Abacavir/Lamivudine) — Central Institute of Epidemiology, Moscow, Russia. This combination uses raltegravir (an integrase inhibitor) and abacavir/lamivudine (nucleoside reverse transcriptase inhibitors) to block HIV replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Raltegravir; Abacavir/Lamivudine TARGET	Raltegravir; Abacavir/Lamivudine	Central Institute of Epidemiology, Moscow, Russia	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase; HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Raltegravir and truvada	Raltegravir and truvada	The University of Texas Health Science Center, Houston	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
DTG/3TC	DTG/3TC	University of Nairobi	marketed	Antiretroviral combination (integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor)	HIV integrase; HIV reverse transcriptase
Switch to DTG + 3TC	Switch to DTG + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Central Institute of Epidemiology, Moscow, Russia · 1 drug in this class
2. Harvard School of Public Health (HSPH) · 1 drug in this class
3. Juan A. Arnaiz · 1 drug in this class
4. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
5. Prism Health North Texas · 1 drug in this class